A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease

Thrombosis Journal

Volumn 3, Issue , 2005, Pages

  Brophy, Donald F ^a,b   Martin, Rika J ^b   Gehr, Todd W B ^b   Carr Jr , Macus E ^b  

^a Virginia Commonwealth University/Medical College of Virginia Campus ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Platelet function; Renal dysfunction; Thrombin generation

Indexed keywords

ENOXAPARIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; HYPERCOAGULABILITY; HYPOTHESIS; MALE; THROMBIN TIME; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; YOUNG MODULUS;

EID: 27444442643     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-3-3     Document Type: Article

References (36)

1. Carr ME: Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001, 15:44-54.
2. Ishii M, Kameyama M, Inokuchi T, Isogai S: Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics. Diabetes Res Clin Pract 1987, 4:45-50.
3. Rosove MH, Frank HJ, Harwig SS: Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus. Diabetes Care 1984, 7:174-79.
4. Small M, Douglas JT, Lowe GD, MacCuish AC, Forbes CD: Effect of insulin therapy on coagulation and platelet function in type II (non-insulin-dependent) diabetes mellitus. Haemostasis 1986, 16:417-23.
5. Borsey DQ, Prowse CV, Gray RS, Dawes J, James K, Elton RA, et al.: Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol 1984, 37:659-64.
6. Reverter JL, Reverter JC, Tassies D, Rius F, Monteagudo J, Rubies-Prat J, et al.: Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997, 56:93-9.
7. Yokoyama H, Myrup B, Rossing P, Ostergaard PB: Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care 1996, 19:441-45.
8. Lopez Y, Paloma MJ, Rifon J, Cuesta B, Paramo JA: Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999, 93:71-78.
9. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, et al.: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992, 67:643-54.
10. Nagai T: Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy. J Atheroscler Thromb 1994, 1:37-40.
11. Yagame M, Eguchi K, Suzuki D, Machimura H, Takeda H, Inoue W, et al.: Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma. J Diabet Complications 1990, 4:175-78.
12. Jones RL, Peterson CM: Hematologic alterations in diabetes mellitus. Am J Med 1981, 70:339-52.
13. Haffner SJ, Cassells H: Hyperglycemia as a cardiovascular risk factor. Am J Med 2003, 115(Suppl 8A):6S-11S.
14. Calles-Escandon J, Garcia-Rubi E, Mirza S, Mortensen A: Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis 1999, 10:23-30.
15. American Diabetes Association: Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl 1):S79-S83.
16. Salvati F, Liani M: Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 2001, 24:131-5.
17. Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK: Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994, 5:36-46.
18. Sloand JA, Sloand EM: Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997, 8:799-803.
19. Sreedhara R, Itagaki I, Hakim RM: Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996, 27:355-64.
20. Nomura S, Hamamoto K, Kawakatsu T, Kido H, Yamaguchi K, Fukuroi T, et al.: Analysis of platelet abnormalities in uremia with and without Glanzmann's thrombasthenia. Nephron 1994, 68:442-48.
21. Carr ME, Martin EJ, Kuhn JG, Spiess MD: Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J Thromb Haemost 2003, 1:1977-83.
22. Krishnaswami A, Carr ME, Jesse RL, Kontos MC, Minisi AJ, Ornato JP, et al.: Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thromb Haemost 2002, 88:739-44.
23. Carr ME, Krishnaswami A. Martin EJ: Platelet contractile force (PCF) and clot elastic modulus (CEM) are elevated in diabetic patients with chest pain. Diabet Med 2002, 19:862-66.
24. Carr ME: Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 2003, 38:55-78.
25. Carr ME, Angchaisuksiri P, Carr SL, Martin EJ: Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood. Cell Biochem Biophys 2003, 39:89-99.
26. Carr ME, Martin EJ, Kuhn JG, Seremetis SV: Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 2003, 89:803-11.
27. Brophy DF, Martin EJ, Gehr TWB, Carr ME: Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004, 44:270-277.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-70.
29. Garcia Frade LJ, de la Calle H, Alava I, Navarro JL, Creighton LJ, Gaffney PJ: Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res 1987, 47:533-40.
30. Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D, Bloom A. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983, 69:254-9.
31. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S: Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985, 79:552-59.
32. Sagripanti A, Barsotti G: Bleeding and thrombosis in chronic uremia. Nephron 1997, 75:125-39.
33. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, et al.: Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 1983, 71:762-68.
34. Weigert AL, Schafer AI: Uremic bleeding: pathogenesis and therapy. Am J Med Sci 1998, 316:94-104.
35. Zwaginga JJ, Ijsseldijk MJ, de Groot PG, Vos J, de Bos Kuil RL, Sixma JJ: Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arterioscler Thromb 1991, 11:733-44.
36. Brophy DF, Martin EJ, Carr SL, Kirschbaum BL, Carr ME: Comparison of Platelet Contractile Force and Bleeding Time in Chronic Hemodialysis Patients. Am J Kidney Dis 2005 in press.